Table 2.

Summary of the available evidence for withdrawal of immunosoppressive drugs in inflammatory bowel disease

Drug	Minimum therapy duration before withdrawal, yr	Estimated risk of disease relapse after withdrawal	Therapeutic drug monitoring before withdrawal	Estimated efficacy of re-treatment	De-escalation
Immunomodulators (thiopurine in CD/UC or methotrexate in CD)	3-5	30% by 2, 50%–75% by 5 yr	No data available	75%-90% (often in combination with steroids)	Possible in combination therapy
Anti-TNF	1-2	30%–40% at 6 mo/1 year and > 50% by 2 yr	Possible	80%-90%	Possible (TDM suggested)
Vedolizumab	No data available	65% by 1.5 yr	No data available	50%-65%	No IBD data available beyond 8 wk
Ustekinumab	No data available	59.5% by 1 yr in registrative studies	No data available	39.2%-64% in registrative studies	No IBD data available beyond 12 wk
Tofacitinib	No data available	65 % by 6 mo, 80 % by 1 yr in registrative studies	No data available	75% after 2 months and 50 % after 3 yr in registrative studies	No IBD data available for dosage < 5 mg bid

CD: Crohn’s disease; UC: Ulcerative colitis; TDM: Therapeutic drug monitoring.